Bill Miller
Miller Value Partners
Bill Miller Alaunos Therapeutics Inc stake
total: 463
Miller Value Partners TCRT trades
- Total transactions:
- 25
- New positions:
- 1
- Sold out:
- 1
- Added:
- 11
- Reduced:
- 12
- Held since:
- 2015 Q1
- Held for:
- 26 quarters
- Latest activity:
- 2021 Q3
According to 2026 Q2 report, Bill Miller doesn't hold any Alaunos Therapeutics Inc (TCRT) shares. To date, the estimated cost basis is nearly $5.66 for "buy" trades and estimated average "sell" price is $2.87. Miller Value Partners first purchased TCRT in 2015 Q1, initially acquiring about 3.00M shares. Since the initial investment in Alaunos Therapeutics Inc (TCRT), Miller Value Partners has made 24 more transactions.
When did Bill Miller sell Alaunos Therapeutics Inc (TCRT)?
Bill Miller sold off the entire Alaunos Therapeutics Inc (TCRT) position in 2021 Q3.
When did Bill Miller buy Alaunos Therapeutics Inc (TCRT)?
Bill Miller first invested in Alaunos Therapeutics Inc (TCRT) in 2015 Q1 at the reported quarter-end price of $10.77 per share.
What's the cost basis of Miller Value Partners's TCRT stake?
The estimated cost basis for Alaunos Therapeutics Inc (TCRT) stake is around $5.66 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $5.66
- Weighted AVG sell price:
- $2.87
Bill Miller's historical trades in Alaunos Therapeutics Inc
25 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q3
|
0.00%
|
0
|
$2.64
|
|
-100% (-10,317,698)
|
-0.71%
|
|
2021 Q2
|
0.71%
|
10,317,698
|
$2.64
|
$27,238,000
|
-12.82% (-1,516,969)
|
-0.11%
|
|
2021 Q1
|
1.21%
|
11,834,667
|
$3.60
|
$42,605,000
|
-5.07% (-631,581)
|
-0.08%
|
|
2020 Q4
|
1.06%
|
$2.52
|
+0.65% (+80,662)
|
|||
|
2020 Q3
|
1.24%
|
$2.52
|
-1.86% (-234,144)
|
|||
|
2020 Q2
|
1.84%
|
$3.28
|
-1.85% (-237,305)
|
|||
|
2020 Q1
|
2.03%
|
$2.45
|
+0.96% (+122,800)
|
|||
|
2019 Q4
|
2.15%
|
$4.72
|
-1.92% (-248,911)
|
|||
|
2019 Q3
|
2.25%
|
$4.28
|
+40.52% (+3,743,996)
|
|||
|
2019 Q1
|
1.41%
|
$3.85
|
-0.28% (-25,550)
|
|||
|
2018 Q4
|
0.76%
|
$1.79
|
+92.31% (+4,447,154)
|
|||
|
2018 Q3
|
0.50%
|
$3.20
|
-2.02% (-99,125)
|
|||
|
2018 Q2
|
0.56%
|
$3.02
|
-2.41% (-121,275)
|
|||
|
2018 Q1
|
0.85%
|
$3.92
|
-0.91% (-46,300)
|
|||
|
2017 Q4
|
0.91%
|
$4.14
|
+4.65% (+225,890)
|
|||
|
2017 Q3
|
1.37%
|
$6.14
|
-1.38% (-68,100)
|
|||
|
2017 Q2
|
1.39%
|
$6.22
|
+0.02% (+1,135)
|
|||
|
2017 Q1
|
1.62%
|
$6.34
|
+0.50% (+24,600)
|
|||
|
2016 Q4
|
1.39%
|
$5.35
|
-2.10% (-105,200)
|
|||
|
2016 Q2
|
1.77%
|
$5.49
|
-8.46% (-462,600)
|
|||
|
2016 Q1
|
2.01%
|
$7.42
|
+14.07% (+674,625)
|
|||
|
2015 Q4
|
1.52%
|
$8.31
|
+21.25% (+840,299)
|
|||
|
2015 Q3
|
1.52%
|
$9.01
|
+13.69% (+476,050)
|
|||
|
2015 Q2
|
1.58%
|
$12.00
|
+15.92% (+477,547)
|
|||
|
2015 Q1
|
1.22%
|
$10.77
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.